Table 3.

Changes in the HIV-1-specific T-cell responses by groups and between different timings.

Changes in HIV-specific responses [median (IQR)]
	DCV3 (groups 1 and 3)			Placebo (groups 2 and 4)		p
Week 4	210 (12.50–1,308)			1,480 (310–2,363)		0.08
Week 8	280 (−71.50–939)			535 (−45–1,493)		0.64
Week 16^	660 (169.5–1740)			1,260 (675–4,220)		0.08
	DCV3	Placebo	p	DCV3+IFNα-2a	Placebo+IFNα-2a	p
Week 4	565 (49.75–1,541)	1,950 (1,120–2,363)	0.04	135 (−43.5–1,107)	352.5 (124.5–2,172)	0.35
Week 8	617.5 (2.50–1,348)	1,020 (−230–1,800)	0.53	110 (−91.5–587.5)	350 (−11.75–831)	0.62
Week 16^	735 (113–1,500)	2,568 (808–4,905)	0.07	585 (342.5–2,530)	1,033 (502.5–3,715)	0.62
	DCV3	DCV3+IFNα-2a	p	Placebo	Placebo+IFNα-2a	p
Week 4	565 (49.75–1,541)	135 (−43.50–1,107)	0.52	1,950 (1,120–2,363)	352.5 (124.5–2,172)	0.23
Week 8	617.5 (2.50–1,348)	110 (−91.5–587.5)	0.22	1,020 (−230–1,800)	350 (−11.75–831)	0.33
Week 16^	735 (113–1,500)	585 (342.5–2,530)	0.75	2568 (808–4,905)	1,033 (502.5–3,715)	0.39

Bold means statistically significant.